Practo to raise $100M in pre-IPO round

Practo is set to raise $100 million in a pre-IPO financing round as the Indian health‑tech firm steps up preparations for a public listing targeted for late 2026, Lapaas Voice reported. The round is being positioned to support international expansion — notably into the U.S. and the UAE — and to strengthen Practo’s balance sheet ahead of an intended market debut.

"Analysts suggest that Practo’s move into EBITDA positivity makes it a much stronger candidate for a successful listing compared to its loss-making peers," the report said.

Deal context and strategic push

The $100 million pre-IPO raise positions Practo among a growing queue of Indian health‑technology businesses planning public offerings toward the end of 2026. Lapaas Voice named fellow prospective lists such as Pharmeasy — which is navigating the aftermath of a debt restructuring — and Healthium Medtech as contemporaries in the pipeline.

According to the report, the fresh capital will be used in part to accelerate Practo’s international pilot programs, with the company explicitly expanding operations in the U.S. and the UAE. Those markets are being targeted as part of an effort to diversify revenue streams and to build scale outside India prior to an IPO.

• Pre-IPO target: $100 million
• Planned listing window: late 2026
• International focus: United States and United Arab Emirates
• Peers named by Lapaas Voice: Pharmeasy (post‑debt restructuring), Healthium Medtech
• Valuation / profitability note: analysts point to EBITDA positivity as a listing strength

Why EBITDA positivity matters

Lapaas Voice’s coverage underscores a market shift in investor scrutiny: profitability metrics such as EBITDA are being viewed as increasingly important for IPO candidates. The report highlighted analyst commentary that Practo’s movement into EBITDA positive territory should make it a more attractive and viable candidate for public markets relative to rivals still reporting losses.

That contrast is especially relevant given the recent paths of some health‑tech companies. The report specifically mentions Pharmeasy’s debt restructuring as a backdrop to the current IPO wave, suggesting that investors and regulators are closely watching balance‑sheet stress and quality of earnings as companies prepare to list.

Outlook

If completed, the $100 million pre-IPO round would give Practo additional firepower to scale international pilots and shore up its public‑market readiness. Lapaas Voice describes the outlet itself as "a business and innovation news platform covering startups, funding updates, case ..." and places Practo’s move within a broader Indian health‑tech push toward public listings in late 2026.

Markets will watch how Practo deploys the proceeds, whether the company sustains EBITDA positivity through the growth push, and how comparable listings from the sector — including Pharmeasy and Healthium Medtech — perform as the IPO window approaches.